Drug profiling agreement with Sanofi announced by Dualsystems Biotech
13.03.2012
Under the new agreement, Dualsystems Biotech will use its drug profiling platform to identify molecular targets for an undisclosed small molecule drug candidate of Sanofis oncology discovery pipeline. Dualsystems Biotech as a partner will contribute to the identification of new targets and elucidation of the mechanism of action of a novel class of compounds.
Dualsystems is continuously expanding its international client base with a strong focus on North America and Europe, which present significant business opportunities. The Zurich-Based Company is a leading service provider in drug and target profiling, serving the international research community in the pharmaceutical - for example Sanofi - biotech, agchem and cosmetic industries as well as academia. Dualsystems Biotech’s unique and comprehensive screening platforms enable the identification of small molecule-protein and protein-protein interactions in any cellular setting. Dualsystems Biotech’s drug and target profiling technologies have significant advantages in cost, speed and sensitivity compared to similar screening technologies for small molecules currently available. They are a powerful tool to accelerate drug target discovery and elucidation of mechanism of action and off-target effect identification in key therapeutic areas.
Please login or sign up to comment.
Commenting guidelines